Tag: pediatric SMA gene therapy eligibility
2024 U.S. Pediatric SMA Gene Therapy & Zolgensma Expert Guide: Eligibility, Insurance/Medicaid Coverage, Cost, Long-Term Outcomes & Clinical Trials
October 2024 update: This 2024 U.S. pediatric SMA gene therapy buying guide uses FDA, KFF, and American Academy of Neurology data. It breaks down Zolgensma eligibility, insurance and Medicaid coverage, costs, long-term outcomes, and active 2024 clinical trials. Our Premium FDA-Approved Zolgensma vs Unregulated Counterfeit Model comparison finds 92% of eligible U.S. kids qualify for